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COVID-19-associated CNS Demyelinating Diseases
Dhanashri Miskin, MD
Comprehensive MS Center
Clinical Assistant Professor
Division of Neuroimmunology
Department of Neurology
Neurological manifestations of SARS-CoV-2 infection are increasingly being recognized. The most
common neurologic symptoms include headache, anosmia, and dysgeusia, but patients may also develop
other central nervous system (CNS) diseases. If we focus on the coronavirus family, there is clear evidence
of its neurotropic character as demyelinating disease has been previously reported with MERS and SARSCoV-1 (Dessau, 2001). However, data remains limited in terms of cases of CNS post-infectious
demyelinating/inflammatory disease following COVID-19. Recent studies have shown that the novel
coronavirus appears to cross the blood-brain barrier and cause acute or delayed CNS demyelination or
axonal damage (Desforges, 2020). A variety of mechanisms have been postulated including virus-induced
hypercoagulable or pro-inflammatory states, direct viral invasion of the CNS, and post-infectious immunemediated processes.
The first radiologic description of neurologic complications due to SARS-CoV-2 infection was described
by Poyiadji et al. with a case of acute necrotizing encephalopathy (ANE), probably related to virus-induced
cytokine storm. For SARS CoV-2 infection, the pro-inflammatory state induced by the cytokine storm,
mainly sustained by IL-1, IL-6, and TNF-α, may be responsible for the activation of glial cells with
subsequent demyelination (Mehta, 2020). A possible alternative could be the production of antibodies
against glial cells triggered by the virus, as a para-infectious or post-infectious phenomenon.
Coronaviruses have been associated with other demyelinating pathologies like acute or subacute
disseminated encephalomyelitis (ADEM) in humans (Yeh, 2004). ADEM is a rare acute inflammatory
demyelinating disease that may follow viral infections. The first case of COVID-19 associated ADEM was
described in a 40-year-old woman (Zhang, 2020). Another case of ADEM was reported in a 54-year-old
woman following COVID-19 disease. SARS-CoV-2 was not detected in the CSF probably because the
neurological damage was sustained by a delayed immune response occurring after the viremia (Zanin,
2020). The first reported case of SARS-CoV-2 causing acute transverse myelitis was reported from Wuhan,
China, where the outbreak first began, and the second case from Boston (Zhao 2020, Sarma 2020). Since
then, a few cases from different parts of the world have also been reported.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS. The cause of MS is
so far unknown, but both genetic and environmental factors are considered important. Environmental
factors, especially viruses, have been associated with the development of demyelinating disease, but no
specific agent has yet been definitively linked to MS. For example, Epstein-Barr virus infection is
considered an important risk factor for the development of MS (Donati, 2020). SARS-CoV-2 may play a
role of infective trigger, similar to the one of Epstein Barr virus in MS. The presence of demyelination, as
well as SARS virus particles and genome sequences, in the brain has been detected in autopsy studies
(Zhang, 2003).
At Thomas Jefferson University Hospital, we recently described the first case of Neuromyelitis optica
(NMO) potentially triggered by SARS-CoV-2 infection. NMO is a rare, inflammatory demyelinating
disease of the CNS, predominantly affecting the optic nerves and spinal cord. NMO is diagnosed by the
presence of at least 1 of 6 core clinical characteristics and detection of NMO/AQP4 IgG. The core clinical
characteristics each implicate 1 of 6 CNS regions: optic nerve, spinal cord, area postrema of the dorsal
medulla, brainstem, diencephalon, or cerebrum (Wingerchuk, 2015). Our patient met criteria for NMO
based on the following 2 clinical characteristics: longitudinally extensive transverse myelitis (spinal cord
lesion spanning greater than 3 segments) and area postrema syndrome (dorsal medullary lesion) in the
setting of positive NMO/AQP-4 serum antibodies.
In all forms of demyelinating disease described above, causality remains difficult to prove, but the temporal
relationship between SARS-CoV-2 infection and the onset/diagnosis of demyelinating event is compelling

for parainfectious phenomenon.
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